DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS In this Clinical Advances in Hematology & Oncology Q&A with Dr. Tapan M. Kadia, an associate professor at the MD Anderson Cancer Center, the current treatments for acute myeloid leukemia (AML) are discussed, with a specific focus on the targeted FLT3 approach, the role of the gene in AML, the differences among the approved FLT3 inhibitors, and why newer FLT3 inhibitors are needed.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
